- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Joe O'Sullivan: We Are Getting Better at Treating Prostate Cancer Earlier
New therapies and imaging modalities have helped providers treat patients who have prostate cancer earlier, said Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
Transcript
New therapies and imaging modalities have helped providers treat patients who have prostate cancer earlier, said Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
Are we getting better at identifying patients with prostate cancer who are likely to relapse and who might need treatment intensification?
I think we are. I think the reason we are getting better at that is because now we have therapies for those patients. When I started treating prostate cancer, first, there really wasn’t a huge benefit in finding out early that somebody had metastasized, because all we had was castration therapy. Now that we have multiple therapies, and also now that we are also getting more ambitious with treatment like stereotactic radiotherapy for oligometastatic prostate cancer, there’s now good value in discovering recurrences at an earlier stage.
In tandem with that, as well as therapeutic research going well, we have a lot of new imaging modalities—whole body MRI, PSMA-PET scans—these are helping us to see a bit deeper inside the patient and maybe identify disease at an earlier stage when it might benefit from therapy.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR
May 5th 2025KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).
Read More
